Go to deals
Healthcare

EyeTechCare has raised US$9 million

EyeTechCare has raised US$9 million, with funds provided by Lyon-based insurance company SHAM, a first time investor, and Crédit Agricole Private Equity (CAPE), one of EyeTechCare’s existing shareholders.

Founded in 2008 and based in Rillieux-la-Pape, near Lyon, France, EyeTechCare provides innovative medical non-invasive devices to permanently cure glaucoma, the first cause of blindness in developed countries.

The funds raised in this second financing will be used to complete the first clinical trial on humans, as well as establish the manufacturing facilities and the sales and marketing force required for this first product. The market launch is scheduled for early 2011.

Oaklins’ team in France reviewed the strategy with the board and organized a fundraising with specialized venture funds.

Talk to the deal team

Thibaut de Monclin

Managing Partner
Paris, France
Oaklins France

Related deals

Leika Medical Equipments Ltd. has been acquired by Angus Capital
Private Equity | Healthcare

Leika Medical Equipments Ltd. has been acquired by Angus Capital

The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.

Learn more
Phen’X Technologies has sold a majority stake to Ciclad
Private Equity | Healthcare | Industrial Machinery & Components

Phen’X Technologies has sold a majority stake to Ciclad

The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.

Learn more
Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Healthcare | TMT

Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments

Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).

Learn more